Compare AdaptHealth Corp (AHCO) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Becton Dickinson and Co — how do they compare? AdaptHealth Corp trades at $5.75 (market cap $771.10M), while Becton Dickinson and Co trades at $182.63 (market cap $50.00B). The key difference: Becton Dickinson and Co is far larger — about 64.8× AdaptHealth Corp's market cap, and Becton Dickinson and Co pays a 2.29% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | BDX | |
|---|---|---|
Market Cap | $771.10M | $50.00B |
Sector | Health | Health |
52-Week High | $13.38 | $185.39 |
52-Week Low | $5.22 | $138.62 |
Enterprise Value | $2.79B | $66.10B |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.77, up 2.12% today, but faces a bearish technical trend with recent earnings misses and a net loss of $70.79 million in 2025. Revenue grew to $3.24 billion, yet profitability remains challenged with a negative net margin. The company is refocusing on sleep and respiratory care after selling its diabetes unit, but faces multiple securities fraud investigations following a significant Q2 2026 earnings shortfall.
The outlook is cautious; while analyst consensus is bullish with a $11.00 price target, near-term risks from legal probes, execution missteps, and margin pressure outweigh potential upside. Investor sentiment is negative due to guidance cuts and operational challenges, making the stock high-risk despite its low valuation multiples.
BDX trades at $181.97, up 0.31% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results showing 4.4% FX-neutral revenue growth to $5 billion. Analyst consensus is mixed with 47% buy ratings and a $183 price target, while strong cash flow generation supports dividend payments of $1.05 quarterly.
BDX demonstrates solid fundamental performance with consistent revenue growth and dividend reliability, though net margins remain compressed at 4.19%. Key risks include tariff pressures and competitive market dynamics. The stock trades near analyst targets with balanced institutional sentiment suggesting moderate upside potential amid ongoing operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
